Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 6:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 927 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Vascular Disease Risk Clear all
Active, not recruiting Not applicable Interventional

The Genomic Medicine at VA Study

NCT04331535
View directory record Official record
Conditions
Coronary Artery Disease, Atrial Fibrillation, Type 2 Diabetes, Colorectal Cancer, Breast Cancer, Prostate Cancer
Interventions
Polygenic risk score (PRS)
Diagnostic Test
Lead sponsor
Boston VA Research Institute, Inc.
Other
Eligibility
50 Years to 70 Years
Enrollment
1,071 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 16, 2026, 6:18 AM EDT
Terminated No phase listed Observational Results available

A Study in the United Sates That Looks at the Safety and Effectiveness of Pradaxa Pellets in Children Aged 3 Months to Less Than 12 Years Who Need Treatment of a Blood Clot or Who Have Had a Blood Clot and Are at Risk of Developing Another Blood Clot

NCT05966740
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Not listed
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
3 Months to 12 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
10
States / cities
La Jolla, California • San Diego, California • New Haven, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 16, 2026, 6:18 AM EDT
Completed Phase 2 Interventional Results available

Rituximab and Cyclophosphamide in Treating Patients With High Risk, Refractory, or Relapsed Multiple Myeloma

NCT00258206
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
rituximab, cyclophosphamide
Biological · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 6, 2017 · Synced Oct 16, 2026, 6:18 AM EDT
Not yet recruiting Not applicable Interventional

MM-CARE: Cardiovascular Risk Assessment in Adults With Multiple Myeloma

NCT07783607
View directory record Official record
Conditions
Multiple Myeloma, Heart Disease Risk Factors
Interventions
Oncology-Embedded Cardiovascular Risk Assessment Pathway, Primary Care Provider-Directed Cardiovascular Risk Assessment Pathway
Other
Lead sponsor
University of Vermont Medical Center
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2028
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 16, 2026, 6:18 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006)

NCT00542971
View directory record Official record
Conditions
AML, Acute Myeloid Leukemia, Myelodysplastic Disorders
Interventions
Idarubicin, Sorafenib, Ara-C
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
15 Years to 60 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 23, 2018 · Synced Oct 16, 2026, 6:18 AM EDT
Completed Phase 1 Interventional

A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies

NCT00807677
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia, Multiple Myeloma, Waldenstrom's Macroglobulinemia, Myelodysplastic Syndrome, Philadelphia Chromosome-negative CML, Myeloid Metaplasia, Myelofibrosis, Advanced Polycythemia, Non-Hodgkins Lymphoma
Interventions
TAK-901
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 2, 2013 · Synced Oct 16, 2026, 6:18 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System

NCT01143454
View directory record Official record
Conditions
Metabolic Disease, Obesity, Li-Fraumeni Syndrome, Cardiomyopathy, Atherosclerosis, Inflammatory Disease
Interventions
NSR IDE-MRI: Research pulse sequences
Device
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
1 Year to 100 Years
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2010
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 16, 2026, 6:18 AM EDT
Completed Phase 1 Interventional

Vismodegib After Stem Cell Transplant in Treating Patients With High-Risk First Remission or Relapsed Multiple Myeloma

NCT01330173
View directory record Official record
Conditions
DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
Vismodegib, Pharmacological Study, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 23, 2014 · Synced Oct 16, 2026, 6:18 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

NCT05739383
View directory record Official record
Conditions
Primary Prevention of Atherosclerotic Cardiovascular Disease
Interventions
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, Placebo in 1.5ml
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years to 79 Years
Enrollment
14,012 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
242
States / cities
Birmingham, Alabama • Fairhope, Alabama • Foley, Alabama + 188 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 16, 2026, 6:18 AM EDT
Completed Phase 2 Interventional Results available

Bortezomib, Doxorubicin Hydrochloride Liposome, and Dexamethasone Followed by Thalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Multiple Myeloma

NCT00458705
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
bortezomib, dexamethasone, pegylated liposomal doxorubicin hydrochloride, thalidomide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 22, 2016 · Synced Oct 16, 2026, 6:18 AM EDT
Completed Phase 3 Interventional Results available

Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS

NCT02525939
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
dalcetrapib, Placebo
Drug
Lead sponsor
DalCor Pharmaceuticals
Industry
Eligibility
45 Years and older
Enrollment
6,147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
122
States / cities
Alexander City, Alabama • Huntsville, Alabama • Mobile, Alabama + 119 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Oct 16, 2026, 6:18 AM EDT
Suspended No phase listed Observational

Evaluation Using ClearView in Determining Association to the Cardiac Risk Factors

NCT01740739
View directory record Official record
Conditions
Cardiovascular Diseases, Coronary Artery Disease
Interventions
Not listed
Lead sponsor
Epic Research & Diagnostics, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Mission Viejo, California
Source: ClinicalTrials.gov public record
Updated Jun 14, 2013 · Synced Oct 16, 2026, 6:18 AM EDT
Completed No phase listed Observational

Stress-Delta Biomarkers for Acute Coronary Syndrome Risk Stratification

NCT02717702
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
40 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Oct 16, 2026, 6:18 AM EDT
Completed Phase 2 Interventional Results available

Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden

NCT00651937
View directory record Official record
Conditions
Multiple Myeloma, Primary Amyloidosis
Interventions
Melphalan, Stem Cell Infusion, Questionnaires, Granulocyte-colony stimulating factor (G-CSF), Apheresis
Drug · Procedure · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
60 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 14, 2020 · Synced Oct 16, 2026, 6:18 AM EDT
Completed No phase listed Observational

Anticoagulation Length of ThErapy and Risk of New Adverse evenTs In Venous thromboEmbolism Study

NCT03292666
View directory record Official record
Conditions
Venous Thromboembolism, Anticoagulants and Bleeding Disorders
Interventions
Oral Anticoagulant
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
39,603 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
2
States / cities
Oakland, California • Pasadena, California
Source: ClinicalTrials.gov public record
Updated Nov 2, 2022 · Synced Oct 16, 2026, 6:18 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Qungasvik (Toolbox)-Healthy Hearts: A Cultural Approach to Reducing Chronic Disease Risk

NCT07829341
View directory record Official record
Conditions
Cardio Vascular Disease, Cerebro Vascular Disease, Mental Health, Chronic Disease (Physical)
Interventions
Qungasvik-Healthy Hearts
Behavioral
Lead sponsor
University of Alaska Fairbanks
Other
Eligibility
12 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Fairbanks, Alaska
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 16, 2026, 6:18 AM EDT
Not yet recruiting No phase listed Observational Accepts healthy volunteers

The RISC Registry--Risk Informed Screening Registry

NCT05848856
View directory record Official record
Conditions
Breast Cancer Risk, Cardiovascular Disease Risk, Cardiometabolic Risk, Diabetes
Interventions
Breast Cancer, Cardiometabolic, Cardiovascular Risk Screening and Follow up
Behavioral
Lead sponsor
Precision Health Equity Initiative
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
10,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2035
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Oct 16, 2026, 6:18 AM EDT
Completed Not applicable Interventional Results available

Stress Management and Biomarkers of Risk in Cardiac Rehabilitation

NCT00981253
View directory record Official record
Conditions
Coronary Heart Disease
Interventions
SMT-enhanced Cardiac Rehabilitation, Standard Cardiac Rehabilitation
Behavioral
Lead sponsor
Duke University
Other
Eligibility
35 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 1, 2018 · Synced Oct 16, 2026, 6:18 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Dietary Salt Intake and Vascular Function

NCT00590512
View directory record Official record
Conditions
Healthy
Interventions
High sodium, Low sodium
Dietary Supplement
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 35 Years · Male only
Enrollment
133 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 29, 2013 · Synced Oct 16, 2026, 6:18 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Transient Ischemic Attack (TIA) Triage and Evaluation of Stroke Risk

NCT01423201
View directory record Official record
Conditions
Cerebrovascular Accident
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
Not listed
Enrollment
262 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2017
U.S. locations
3
States / cities
Davis, California • Stanford, California • Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 11, 2019 · Synced Oct 16, 2026, 6:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Anticoagulation Medical Home

NCT02870296
View directory record Official record
Conditions
Venous Thromboembolism, Patient-Centered Care
Interventions
Enhanced Assessment and Education
Behavioral
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 16, 2018 · Synced Oct 16, 2026, 6:18 AM EDT
Completed Phase 2 Interventional Results available

Trial to Evaluate the Effect of ALN-PCSSC Treatment on Low Density Lipoprotein Cholesterol (LDL-C)

NCT02597127
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease, Familial Hypercholesterolemia, Diabetes
Interventions
ALN-PCSSC, Normal Saline
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years to 99 Years
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
8
States / cities
Jacksonville, Florida • Indianapolis, Indiana • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated May 17, 2019 · Synced Oct 16, 2026, 6:18 AM EDT
Completed Phase 4 Interventional Results available

A Study of Stress Echocardiography in Post-Menopausal Women at Risk for Coronary Disease

NCT00162370
View directory record Official record
Conditions
Coronary Artery Disease, Heart Disease
Interventions
Perflutren Lipid Microsphere Injectable Suspension
Drug
Lead sponsor
Lantheus Medical Imaging
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 15, 2021 · Synced Oct 16, 2026, 6:18 AM EDT
Completed Phase 3 Interventional Results available

The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial

NCT00799903
View directory record Official record
Conditions
Atherosclerosis
Interventions
Darapladib, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
15,828 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
155
States / cities
Birmingham, Alabama • Huntsville, Alabama • Anchorage, Alaska + 132 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2017 · Synced Oct 16, 2026, 6:18 AM EDT